Sensorion receives FDA IND approval for Arazasetron (SENS-401). pdfRead

Sensorion announces an oral presentation at the 5th congress of European ORL-Head & Neck Surgery in Brussels. pdfRead

Sensorion receives European Medicines Agency agreement on the Pediatric Investigation Plan (PIP) for Arazasetron  (SENS-401) in two indications. pdfRead

Sensorion announces that the “AUDINNOVE” project of which Sensorion is a partner is a laureate of the fourth solicitation request for funding from RHU as part of the French “Avenir investment program”. pdfRead

Sensorion announces a €20m convertible bond issue subscribed by two renowned investors Invus and Sofinnova Partners. pdfRead